Cargando…

Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines

PURPOSE: To investigate the IOP lowering effect and safety of tafluprost 0.0015% in a routine clinical setting in the Philippines. PATIENTS AND METHODS: A retrospective review of glaucoma patients receiving tafluprost 0.0015% (BAK 0.001% preserved) with a minimum follow-up of 3 months was conducted....

Descripción completa

Detalles Bibliográficos
Autores principales:	Tumbocon, Joseph Anthony, Macasaet, Anne Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717730/ https://www.ncbi.nlm.nih.gov/pubmed/31695311 http://dx.doi.org/10.2147/OPTH.S209942

Ejemplares similares

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
por: Hwang, Young Hoon
Publicado: (2014)

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
por: Lee, Wonseok, et al.
Publicado: (2017)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
por: Takagi, Yasutaka, et al.
Publicado: (2016)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat, Lutz E, et al.
Publicado: (2017)

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
por: Pfeiffer, Norbert, et al.
Publicado: (2014)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
por: Rolle, Teresa, et al.
Publicado: (2017)

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
por: Wong, Tina T, et al.
Publicado: (2018)

DRAFT ATLAS ATRECON manual (Version 0.015)
por: Offline Software Group
Publicado: (1994)

Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience
por: Lin, Ju-Kuo, et al.
Publicado: (2022)

A Pooled Assessment of Ocular Surface Disease After Switching from Preserved Prostaglandins to Tafluprost Across Six Countries in Asia
por: Tumbocon, Joseph Anthony, et al.
Publicado: (2022)

Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2018)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Efficacy, safety and tolerability of field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a single center case series
por: Bobyr, Ivan, et al.
Publicado: (2016)

Progression to blindness in 20 years among patients with glaucomatous visual field loss in a tertiary hospital in the Philippines
por: Cabrera, Cathleen Camille, et al.
Publicado: (2020)

Epidemiology of Cholera in the Philippines
por: Lopez, Anna Lena, et al.
Publicado: (2015)

Efficacy of 0.015% intracameral epinephrine for significant miosis induced by photodisruption during femtosecond laser-assisted cataract surgery
por: Jun, Jong Hwa, et al.
Publicado: (2018)

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
por: Kitamura, Kazuyoshi, et al.
Publicado: (2018)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
por: Kim, Joon Mo, et al.
Publicado: (2021)

Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015%
por: Jung, Yu Seok, et al.
Publicado: (2016)

Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel
por: Iannazzone, Silvia S., et al.
Publicado: (2018)

Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives
por: Gameiro, Luiz, et al.
Publicado: (2019)

Intestinal Capillariasis, Western Mindanao, the Philippines
por: Belizario, Vicente Y., et al.
Publicado: (2010)

Effects of Tafluprost on Ocular Blood Flow
por: Zhang, Xinyue, et al.
Publicado: (2022)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate, Ngamkae, et al.
Publicado: (2020)

Remarks made by Dr Pennetta Relating to Document CERN/FC/0015
Publicado: (1954)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda, Yoko, et al.
Publicado: (2016)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
por: Miki, Atsuya, et al.
Publicado: (2022)

Run no. 264, 1.12.1972, 26 GeV, 20b, Stacking with E = 0.015 for different RF parameters
por: Hansen, S
Publicado: (1972)

Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis
por: Goldenberg, Gary, et al.
Publicado: (2014)

Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study
por: Emilio, Joanna, et al.
Publicado: (2016)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi, Matteo, et al.
Publicado: (2014)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Pozarowska, Dorota
Publicado: (2010)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

A Comprehensive Evaluation of the Attenuation Characteristics of Some Sliding Bearing Alloys under 0.015–15 MeV Gamma-Ray Exposure
por: Algethami, Merfat, et al.
Publicado: (2022)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
por: Niwano, Yoshimi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nq5ijcckugqtste9mlb1u9bhu2